Jaguar Health Inc., trading under NASDAQ: JAGX, has released a corporate presentation outlining its innovative approach to developing plant-based medicines for gastrointestinal disorders. The presentation highlights the company's key products, including Mytesi, an FDA-approved treatment for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia®-CA1, conditionally approved by the FDA for treating chemotherapy-induced diarrhea in dogs. The document also notes the physiological anti-secretory action of NP-300 and crofelemer, aimed at reducing chloride ion secretion and improving stool consistency. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.